
Medical Policy



Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

Joint Medical Policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and is therefore subject to change.

***Current Policy Effective Date: 3/1/24**
(See policy history boxes for previous effective dates)

Title: Charged-Particle (Proton or Helium Ion) Radiotherapy For Neoplastic Conditions

Description/Background

Charged-particle beams consisting of protons or helium ions are a type of particulate radiotherapy. They have several unique properties that distinguish them from conventional electromagnetic (ie, photon) radiotherapy, including minimal scatter as particulate beams pass through tissue, and deposition of ionizing energy at precise depths (i.e., the Bragg peak). Thus, radiation exposure of surrounding normal tissues is minimized. The theoretical advantages of protons and other charged-particle beams may improve outcomes when the following conditions apply:

- Conventional treatment modalities do not provide adequate local tumor control;
 - Evidence shows that local tumor response depends on the dose of radiation delivered; and
 - Delivery of adequate radiation doses to the tumor is limited by the proximity of vital radiosensitive tissues or structures.
-

Regulatory Status

Radiotherapy is a procedure and, therefore, is not subject to U.S. Food and Drug Administration (FDA) regulations. However, the accelerators and other equipment used to generate and deliver charged particle radiation (including proton beam) are devices that require FDA oversight. Senior staff at the FDA's Center for Devices and Radiological Health indicated that the proton beam facilities constructed in the U.S. prior to enactment of the 1976 Medical Device Amendments were cleared for use in the treatment of human diseases on a "grandfathered" basis, while at least one that was constructed subsequently has received a 510(k)-marketing clearance. There are 510(k) clearances for devices used for delivery of proton beam therapy and devices considered to be accessory to treatment delivery systems such as the Proton Therapy Multileaf Collimator (which was cleared in December 2009). Since

2001, several devices classified as medical charged-particle radiation therapy systems have received 510(k) marketing clearance. FDA Product Code LHN

Medical Policy Statement

Charged-particle irradiation with proton or helium ion beams may be considered established for the curative treatment for specific patient populations. It is a useful therapeutic option when indicated.

Other applications of charged-particle irradiation with proton beams are considered experimental/investigational.

Inclusionary and Exclusionary Guidelines

Inclusions*:

Charged-particle irradiation with proton or helium ion beams is established for the curative treatment of **ANY** of the following conditions when metastatic disease is not present:

- For treatment of small, localized tumors associated with genetic syndromes in which minimizing the total volume of radiated tissue is minimized, for example in individuals with cancer syndromes such as Neurofibromatosis type 1 (NF-1), Li-Fraumeni, Ataxia Telangiectasia (with deleterious ATM mutations), Hereditary Retinoblastoma, Lynch syndrome, or Hereditary Breast or Ovarian Cancer (with BRCA1/2 mutations)
- In the treatment of intracranial arteriovenous malformation not amenable to surgical excision or other conventional forms of treatment OR adjacent to critical structures such as the optic nerve, brain stem or spinal cord
- Re-irradiation with curative intent where cumulative critical structure dose will exceed tolerance dose
- Primary malignant or benign bone tumors
- Primary ocular tumors including intraocular/uveal melanomas
- Base of skull primary tumors (eg, Chordomas, Chondrosarcomas)
- Primary CNS tumors excluding IDH wild-type glioblastoma multiforme
- Primary spine or spinal cord tumors where organs at risk tolerance will be exceeded with photon treatments
- Nonmetastatic primary tumors requiring craniospinal irradiation (eg, medulloblastoma)
- Nasopharynx, nasal cavity, paranasal sinuses or other accessory sinuses cancer
- Unresected T3, T4, or node positive head and neck cancers
- Esophageal cancer
- Thymoma or thymic carcinoma
- Mediastinal lymphomas
- Thoracic sarcomas
- Primary malignant pleural mesothelioma
- Hepatocellular cancer or intrahepatic cholangiocarcinoma
- Retroperitoneal sarcomas
- Individuals with a single kidney or transplanted pelvic kidney with treatment of an adjacent target volume

- Benign or malignant tumors or hematologic malignancies in children aged 21 years and younger treated with curative intent
- In the curative treatment of nonmetastatic primary non-small cell lung cancer

** Use of proton beam therapy (PBT) may require prior authorization to verify that BCBSM/BCN criteria are met and, where appropriate, to explore the appropriateness of using alternative therapeutic modalities such (i.e. IMRT, 3-Dimensional Conformal Radiation Therapy).*

Exclusions:

- Head and neck cancers not included in Group 1 (eg, T1/T2 tumors, node negative tumors, postoperative tumors with negative margins, periorbital tumors)
- Cutaneous tumors with cranial nerve invasion to the base of skull, cavernous sinus and/or brainstem
- Head and neck cancers requiring ipsilateral radiation treatment (eg, oral cavity, salivary gland)
- Mucosal melanoma
- Glioblastoma, IDH wild-type
- Breast cancer, including but not limited to when a photon based plan cannot meet tolerances for organs at risk
- Pancreatic cancer
- Gastric cancer
- Extrahepatic cholangiocarcinoma
- Kidney cancer
- Adrenal cancers
- Liver metastases being treated with curative intent (ie, oligometastases) in which a photon based plan cannot meet tolerances for organs at risk
- Prostate cancer, including but not limited to when a photon based plan cannot meet tolerances for organs at risk
- Colon cancer
- Rectal cancer
- Anal cancer
- Bladder cancer
- Cervical cancer
- Endometrial cancer
- Ovarian Cancer
- Hodgkin Lymphoma
- Non-Hodgkin Lymphoma
- Skin cancer
- Palliative treatment
- Metastatic tumors
- Leptomeningeal disease
- Multiple myeloma
- Pelvic or proximal thigh where use of protons results in significant dose reduction to genitalia

CPT/HCPCS Level II Codes (Note: The inclusion of a code in this list is not a guarantee of coverage. Please refer to the medical policy statement to determine the status of a given procedure.)

Established codes*:

32701 77300 77520 77522 77523 77525

Other codes (investigational, not medically necessary, etc.):

N/A

* Use of PBT may require prior authorization to verify that BCBSM/BCN criteria are met and, where appropriate, to explore the appropriateness of using alternative therapeutic modalities such (i.e. IMRT, 3-Dimensional Conformal Radiation Therapy).

Note: The above code(s) may not be covered by all contracts or certificates. Please consult customer or provider inquiry resources at BCBSM or BCN to verify coverage.

Rationale

Evidence reviews assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to function—including benefits and harms. Every clinical condition has specific outcomes that are important to patients and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of a technology, 2 domains are examined: the relevance and the quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

CHARGED-PARTICLE (PROTON OR HELIUM ION) RADIOTHERAPY FOR UVEAL MELANOMAS

Clinical Context and Test Purpose

The purpose of charged-particle (proton or helium ion) radiotherapy (RT) in patients who have uveal melanoma(s) is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The question addressed in this evidence review is: Does charged-particle RT improve the net health outcome in patients who have uveal melanoma(s)?

The following PICO was used to select literature to inform this review.

Populations

The relevant population of interest is individuals with uveal melanoma(s). Uveal melanoma, although rare, is the most common primary intraocular malignancy in adults. Mean age-adjusted incidence of uveal melanoma in the United States is 6.3 per million people among whites, 0.9 among Hispanics, and 0.24 among blacks. Uveal melanoma has a progressively rising, age-specific, incidence rate that peaks near age 70.(1)

Interventions

The therapy being considered is charged-particle (proton or helium ion) RT. Charged-particle therapy is administered in specially equipped treatment centers. Proton beam therapy can be administered with or without stereotactic techniques.

Comparators

The following practices are currently being used to make decisions about the treatment of uveal melanoma(s): plaque RT, surgical resection, and transpupillary thermotherapy. Primary, localized uveal melanoma can be treated by surgery or RT. In general, larger tumors require enucleation surgery and smaller tumors can be treated with RT, but specific treatment parameters are lacking. The most common treatment of localized uveal melanoma is RT, which is preferred because it can spare vision in most cases. For smaller lesions, RCTs have shown that patients receiving RT or enucleation progress to metastatic disease at similar rates after treatment.(2) RT can be delivered by various mechanisms, most commonly brachytherapy and proton beam therapy (PBT). Treatment of primary uveal melanoma improves local control and spares vision; however, the 5-year survival rate (81.6%) has not changed over the last 3 decades, suggesting that life expectancy is independent of successful local eye treatment.(3)

Outcomes

The general outcomes of interest are overall survival (OS), disease-free survival, change in disease status (local recurrence), and treatment-related morbidity. RT is used as part of first-line treatment for uveal melanoma. One- and 5-year outcomes are indicators of successful treatment.

Systematic Reviews

This section was informed by a TEC Assessment (1996) that concluded proton therapy was at least as effective as alternative therapies for treating uveal melanoma.(4)

Subsequently, Wang et al (2013) published a systematic review of the literature on charged-particle (proton, helium or carbon ion) RT for uveal melanoma.(5) Reviewers included 27 controlled and uncontrolled studies that reported health outcomes (eg, mortality, local recurrence). Three studies were randomized controlled trials (RCTs). One RCT compared helium ion therapy with an alternative treatment (brachytherapy). The other 2 RCTs compared different proton beam protocols so cannot be used to draw conclusions about the efficacy of charged-ion particle therapy relative to other treatments. The overall quality of the studies was low; most of the observational studies did not adjust for potential confounding variables. The analysis focused on studies of treatment-naïve patients (all but one of the identified studies). In a pooled analysis of data from 9 studies, there was no statistically significant difference in mortality rates with charged-particle therapy compared with brachytherapy (odds ratio [OR], 0.13; 95% confidence interval [CI], 0.01 to 1.63). However, there was a significantly lower rate of local recurrence with charged-particle therapy compared with brachytherapy in a pooled analysis of 14 studies (OR, 0.22; 95% CI, 0.21 to 0.23). There were significantly lower rates of radiation retinopathy and cataract formation in patients treated with charged-particle therapy than brachytherapy (pooled rates of 0.28 vs 0.42 and 0.23 vs 0.68, respectively). Reviewers concluded there was low-quality evidence that charged-particle therapy is at least as effective as alternative therapies for primary treatment of uveal melanoma and is better at preserving vision.

Randomized Controlled Trials

An RCT by Mishra et al (2015) compared charged-particle therapy using helium ions and iodine-125 (I-125) plaque therapy in 184 patients with uveal melanoma.(6) The primary end point was local tumor control. Median follow-up was 14.6 years in charged-particle therapy group and 12.3 years in the I-125 plaque therapy group. The rate of local control at 12 years was significantly higher in the helium ion group (98%; 95% CI, 88% to 100%) than the I-125 plaque therapy group (79%; 95% CI, 68% to 87%; $p=0.006$). Overall survival (OS) at 12 years was 67% (95% CI, 55% to 76%) in the helium ion group and 54% (95% CI, 43% to 63%) in the I-125 plaque therapy group ($p=0.02$).

Comparative Observational Studies

Lin et al (2017) published a retrospective review of 1224 patients in the National Cancer Database who had choroid melanoma and were treated with brachytherapy ($n=996$) or proton therapy ($n=228$) between 2004 and 2013.(7) For the brachytherapy group, median follow-up was 37 months; for proton-treated patients, median follow-up was 29 months. Proton-treated patients were propensity-matched with a smaller cohort of brachytherapy-treated patients ($n=228$ each). The OS rate at 2 years was 97% for brachytherapy-treated patients and 93% for proton-treated patients. The 5-year OS rates were 77% and 51% for brachytherapy- and proton-treated groups, respectively ($p=0.008$). Factors likely to predict poorer survival rates included the following: older age (hazard ratio [HR], 1.06; 95% CI, 1.03 to 1.09; $p<0.02$); tumor diameter of 12 to 18 mm (HR=2.48; 95% CI, 1.40 to 4.42; $p<0.02$); tumor diameter greater than 18 mm (HR=6.41; 95% CI, 1.45 to 28.35; $p<0.02$); and proton treatment (HR=1.89; 95% CI, 1.06 to 3.37; $p<0.02$).

Long-Term Studies

Toutee et al (2019) reported 5-year visual outcomes for patients with stage T1 uveal melanoma ($N = 424$) treated by proton therapy, as a function of their distance to the fovea-optic disc in a long-term retrospective study.(8) With a mean follow-up duration of 122

months, no tumor recurrences were observed. Mean baseline and final best corrected visual acuities were measured for patients with posterior edge of tumor located at ≥ 3 mm (n = 75) or < 3 mm (n = 317) as 20/25 & 20/32 and 20/40 & 20/80. The frequency of a 20/200 or greater conservation was 93.2% and 60.1%, respectively (p < .001). Thus, proton beam therapy for stage T1 uveal melanoma was shown to yield excellent tumor control and good long-term visual outcomes, particularly for tumors located ≥ 3 mm from the fovea-optic disc.

Section Summary: Uveal Melanoma

Systematic reviews, including a 1996 TEC Assessment, have concluded that charged-particle RT is at least as effective as alternative therapies for treating uveal melanomas and is better at preserving vision. A 2013 systematic review on charged-particle therapy for uveal melanoma identified 3 RCTs and a number of observational studies. This systematic review found that charged-particle therapy was associated with a significantly lower rate of local recurrence compared with brachytherapy and fewer adverse effects to vision. A 2017 database review found comparable 2-year OS rates but lower 5-year OS rates for PBT than for brachytherapy.

CHARGED-PARTICLE (PROTON OR HELIUM ION) RADIOTHERAPY FOR INDIVIDUALS WITH SKULL-BASED TUMORS

Clinical Context and Test Purpose

The purpose of charged-particle (proton or helium ion) RT in patients who have skull-based tumors is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this review.

Populations

The relevant population of interest is individuals with skull-based tumors. The skull base is the anatomic area that supports the brain and includes the entry and exit passages for nerve and vascular bundles.

Tumors located near these vital structures such as chordoma and chondrosarcoma that arise in the skull base may not be amenable to complete surgical excision or adequate doses of conventional RT are impossible.

Interventions

The therapy being considered is charged-particle (proton or helium ion) RT. Charged-particle irradiation theoretically affords protection from radiation damage to surrounding structures. Charged-particle therapy is administered in specially equipped treatment centers. PBT can be administered with or without stereotactic techniques.

Comparators

The following practices are currently being used to make decisions about skull-based tumors: other types of RT including conventional and high-dose photon therapies, surgical resection, and other therapeutic modalities for localized tumor control.

Outcomes

The general outcomes of interest are OS, disease-free survival, change in disease status (local recurrence), and treatment-related morbidity. Local control and survival outcomes for charged-particle therapy for skull-base tumors have been reported at 1 year and 5 years.

Systematic Reviews

This section was informed by a TEC Assessment (1996) that concluded, compared with treatment using conventional RT after partial resection or biopsy, charged-particle irradiation yields greater rates of local control, OS, and disease-free survival at 5 years after therapy.(4) Subsequently, Lodge et al (2007) published a systematic review of charged-particle therapy found that local tumor control and 5-year OS rates of 63% and 81%, respectively, for skull-based chordomas treated with surgery and PBT.(9) Comparable local tumor control and 5-year OS rates were 25% and 44% for postsurgical photon therapy. For chondrosarcomas of the skull-base, proton therapy achieved a 5-year tumor control rate of 95% and photon therapy a rate of 100%

A meta-analysis review by Zhou et al (2018) compared the effectiveness of photon- and particle-based radiotherapy (RT) for the treatment of chordoma after surgery.(10) A fixed-effects model was used to perform an analysis of 3-, 5-, and 10-year overall survival (OS) rates. A total of 25 studies were included, x on the use of conventional RT (CRT), x on the use of stereotactic RT (SRT), 9 on the use of proton beam therapy (PBT), and 5 on the use of carbon-ion RT (CIRT). A total of 21 studies reported 3-yr OS data, 15 studies reported 5-yr OS data, and 9 studies reported 10-yr OS data.

Section Summary: Skull-Based Tumors

Several systematic reviews, including a TEC Assessment, have been published. A 2007 systematic review found 5-year OS rates of 81% with PBT compared with 44% with surgery and photon therapy. In 2018, a meta-analysis found 5-year and 10-year overall survival rates for proton beam therapy of 78% and 60% compared with 46% and 21% for conventional radiotherapy. The published evidence supports a meaningful improvement in the net health outcome.

CHARGED-PARTICLE (PROTON OR HELIUM ION) RADIOTHERAPY FOR PEDIATRIC CENTRAL NERVOUS SYSTEM TUMORS

Clinical Context and Test Purpose

The purpose of charged-particle (proton or helium ion) RT in children who have central nervous system (CNS) tumors is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this review.

Populations

The relevant population of interest is individuals with pediatric CNS tumors. Primary malignant tumors of the CNS are the second most common childhood malignancies after hematologic malignancies. Specific types include craniopharyngioma, astrocytoma, ependymoma,

glioblastoma, and medulloblastoma. There are multiple genetic syndromes that confer additional risk for the development of CNS tumors: neurofibromatosis, tuberous sclerosis, as well as von Hippel-Lindau, basal cell nevus and Li Fraumeni and Turcot syndromes.

Interventions

The therapy being considered is charged-particle (proton or helium ion) RT. Charged-particle therapy is administered in specially equipped treatment centers. PBT can be administered with or without stereotactic techniques.

Comparators

The following practices are currently being used to make decisions about pediatric CNS tumors: other types of RT, surgical resection, and other therapeutic modalities for localized tumor control.

Outcomes

The general outcomes of interest are OS, disease-free survival, change in disease status (local recurrence), and treatment-related morbidity. Local tumor control and OS would be assessed at 1 and 3 years.

Systematic Reviews

Leroy et al (2016) published a systematic review of the literature on PBT for treatment of pediatric cancers.(11) Their findings included the following:

- For craniopharyngioma, 3 studies were identified: 2 retrospective case series and 1 retrospective comparative study of PBT and intensity-modulated radiotherapy (IMRT). They found very low-level evidence that survival outcomes with PBT and IMRT are similar.
- For ependymoma, 1 prospective case series and another retrospective case series were identified. They concluded that the evidence did not support or refute the use of PBT for this condition.
- For medulloblastoma, 1 prospective case series and 2 retrospective case series were identified. They concluded that the evidence is insufficient to support or refute the use of PBT for this condition.
- For CNS germinoma, 1 retrospective case series was identified. They concluded that the evidence did not support or refute the use of PBT for this condition.

Upadhyay et al (2022) conducted a systematic review and meta-analysis of secondary malignant neoplasm risk in children treated with proton versus photon radiotherapy for primary CNS tumors.(12) Twenty-four studies were included for analysis representing 418 secondary malignancies among 38,163 patients. Most common secondary malignancies included gliomas (40.6%), meningioma (38.7%), sarcoma (4.8%), thyroid cancer (4.2%), and basal cell carcinoma (1.3%). The incidence of secondary malignancies with photons was 1.8% (95% CI, 1.1 to 2.6; I²=94%) compared to 1.5% (95% CI, 0 to 4.5; I²=81%) with protons, and this difference was not significantly different (p=.91). The overall cumulative incidence of secondary malignancies at 10 years ranged from 1.4% to 8.9% for photons versus 0% to 5.4% with protons. A shorter latency to secondary cancers was also observed in proton treated patients (5.9 years vs 11.9 years, respectively). The median follow-up was slightly shorter in the proton group, at 6.9 years compared to 8.8 years in patients treated with photons. The authors suggest this may bias observed outcomes, in addition to general study heterogeneity and potentially confounding effects of concurrent treatment with chemotherapy.

Peterson et al (2022) published a systematic review of neuropsychological outcomes with proton versus photon radiation therapy in the treatment of pediatric brain tumors.(13) Eight

studies were included for analysis. Photon radiation therapy was associated with decreased neuropsychological functioning over time whereas proton radiation therapy was generally associated with stable neuropsychological function across all domains except working memory and processing speed. However, study interpretation is limited by methodological limitations concerning collection and reporting of sociodemographic characteristics for each treatment group.

Case Series

Representative case series of PBT used to treat multiple pediatric CNS tumor types are described next. For example:

Baliga et al (2022) reported on 178 pediatric medulloblastoma patients treated with PBT between 2002 and 2016.(14) Median longitudinal follow-up was 9.3 years with 156 patients (89.3%) undergoing a gross total resection. Ten-year OS for the whole cohort, standard-risk cohort, and intermediate/high-risk cohort was 79.3% (95% CI, 73.1 to 85.9), 86.9% (95% CI, 79.9 to 94.4), and 68.9% (95% CI, 58.7 to 80.8) respectively. Corresponding rates of 10-year event-free survival (EFS) were 73.8% (95% CI, 67.1 to 81.1), 79.5% (95% CI, 71.1 to 88.9), and 66.2% (95% CI, 56.3 to 78.0), respectively. Intermediate/high-risk status was associated with inferior EFS and OS in univariate analysis. The 10-year cumulative incidence of any secondary tumors, secondary malignancies, or secondary benign tumors was 5.6% (95% CI, 2.2 to 11.3), 2.1% (95% CI, 0.6 to 5.8), and 3.4% (95% CI, 0.9 to 8.9), respectively. Two patients who developed in-field secondary glioblastoma died. The cumulative incidence rates of brainstem injury at 5 and 10 years were 1.1% (95% CI, 0.2 to 3.7) and 1.9% (95% CI, 0.5 to 5.1). The authors noted that the 5-year EFS of 83% for standard-risk and 70% for high-risk patients in the St. Jude Medulloblastoma-86 Study which used 3-dimensional conformal RT was comparable to the 5-year EFS rates of 87.3% and 68.9% in this study. Additionally, the rate of secondary malignancies in the proton-treated cohort was nearly half the rate historically observed in patients treated with photons (2.1% vs 3.7%).

Indelicato et al (2018) reported on 179 children with nonmetastatic grade II/III intracranial ependymoma who were treated with proton therapy at a single institution.(15) Three-year local control, progression-free survival, and OS rates were 85%, 76%, and 90%, respectively. The authors noted that these disease control rates were comparable to photon series. The 3-year grade 2+ brainstem toxicity rate was 5.5% (95% CI, 2.9 to 10.2). Subtotal resection and male sex were associated with inferior disease control rates.

Bishop et al (2014) reported on 52 children with craniopharyngioma treated at 2 centers; 21 received PBT and 31 received IMRT.(16) Patients received a median dose of 50.4 Gy. At 3 years, OS was 94.1% in the PBT group and 96.8% in the IMRT group ($p=0.742$). Three-year nodular and cystic failure-free survival rates were also similar between groups. On imaging, 17 (33%) patients had cyst growth within 3 months of RT, and 14 patients had late cyst growth (>3 months after therapy); rates did not differ significantly between groups. In 14 of the 17 patients with early cyst growth, enlargement was transient.

MacDonald et al (2011) reported on the use of protons to treat germ cell tumors in 22 patients, 13 with germinoma and 9 with non-germinomatous germ cell tumors.(17) Radiation doses ranged from 30.6 to 57.6 cobalt Gray equivalents (CGE). All non-germinomatous germ cell tumor patients also received chemotherapy before RT. Median follow-up was 28 months. There were no CNS recurrences or deaths. Following RT, 2 patients developed growth hormone deficiency and 2 other patients developed central hypothyroidism. The authors indicated that longer follow-up was necessary to assess the neurocognitive effects of therapy. In the same study, a dosimetric comparison of photons and protons was performed. PBT provided substantial sparing to the whole brain and temporal lobes, and reduced doses to the optic nerves.

Moeller et al (2011) reported on 23 children enrolled in a prospective series treated with PBT for medulloblastoma between 2006 and 2009.(18) Because hearing loss is common after chemoradiotherapy for children with medulloblastoma, the authors evaluated whether PBT led to a clinical benefit in audiometric outcomes (because, compared with photons, protons reduce radiation dose to the cochlea for these patients). The children underwent pre- and 1-year post-RT pure-tone audiometric testing. Ears with moderate-to-severe hearing loss before therapy were censored, leaving 35 ears in 19 patients available for analysis. The predicted mean cochlear radiation dose was 30 CGE (range, 19-43 CGE). Hearing sensitivity significantly declined following RT across all frequencies analyzed ($p < 0.05$). There was partial sparing of mean post-radiation hearing thresholds at low- to mid-range frequencies; the rate of high-grade (grade 3 or 4) ototoxicity at 1 year was 5%, which compared favorably to the rate of grade 3 or 4 toxicity following IMRT (18%) reported in a separate case series.

Hug et al (2002) reported on proton radiation in the treatment of low-grade gliomas in 27 pediatric patients.(19) Six patients experienced local failure; acute adverse events were minimal. After a median follow-up of 3 years, all children with local control-maintained performance status. In a dosimetric comparison of protons to photons for 7 optic pathway gliomas treated, Fuss et al (1999) showed a decrease in radiation dose to the contralateral optic nerve, temporal lobes, pituitary gland, and optic chiasm with the use of protons.(20)

Section Summary: Pediatric Central Nervous System Tumors

A 2016 systematic review identified several case series evaluating PBT for several types of pediatric CNS tumors including craniopharyngioma, ependymoma, medulloblastoma, and CNS germinoma. One small comparative observational study was identified. It compared PBT with IMRT for children with craniopharyngioma and found similar outcomes with both types of treatment. The current evidence base is not sufficiently robust to draw conclusions about the efficacy of PBT for pediatric CNS tumors. A systematic review of neuropsychological outcomes with proton versus photon radiation therapy for pediatric brain tumors suggests more stable neuropsychologically functioning across time with PBT for most domains, but study interpretation is complicated by incomplete baseline sociodemographic data for each group. Ten-year data in children with medulloblastoma reported OS and event-free survival rates comparable to historical photon-treated cohorts, with reduced incidence of secondary malignancies. While some studies suggest sparing of normal tissues and reduced toxicities, limitations of the published evidence preclude determining the effects of the technology on net health outcome.

CHARGED-PARTICLE (PROTON OR HELIUM ION) RADIOTHERAPY FOR PEDIATRIC NON-CNS TUMORS

Clinical Context and Test Purpose

The purpose of charged-particle (proton or helium ion) RT in children who have non-CNS tumors is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this review.

Populations

The relevant population of interest is individuals with pediatric non-CNS tumors. Tumors of the axial skeleton require conformal radiotherapy with the intent of avoiding damage to vital structures.

Interventions

The therapy being considered is charged-particle (proton or helium ion) RT. Charged-particle therapy is administered in specially equipped treatment centers. PBT can be administered with or without stereotactic techniques.

Comparators

The following practices are currently being used to make decisions about pediatric non-CNS tumors: other types of RT, surgical resection, and other types of therapy for localized tumor control.

Outcomes

The general outcomes of interest are OS, disease-free survival, change in disease status (local recurrence), and treatment-related morbidity. Local control and OS would be assessed at 1 and 3 years.

Case Series

There are scant data on the use of PBT in pediatric non-CNS tumors. Data include dosimetric planning studies in a small number of pediatric patients with parameningeal rhabdomyosarcoma (21) and late toxicity outcomes in other solid tumors of childhood.(22,23)

Vogel et al (2018) published a retrospective case series of proton-based radiotherapy to treat nonhematologic head and neck malignancies in 69 pediatric patients.(24) Thirty-five of the patients had rhabdomyosarcoma and were treated with a median dose of 50.4 Gy (range 36.0-59.4 Gy) in 1.8 Gy fractions. A number of patients had Ewing sarcoma (n=10; median dose, 55.8 Gy; range, 55.8-65.6 Gy), and there were other histologies (n=24; median dose, 63.0 Gy). For the overall cohort, 92% (95% CI, 80% to 97%) were free from local recurrence at 1 year; at 3 years, 85% (95% CI, 68% to 93%). The OS rate at 1 year was 93% (95% CI, 79% to 98%); at 3 years, it was 90% (95% CI, 74% to 96%). Incidences of grade 3 toxicities were as follows: oral mucosities (4%), anorexia (22%), dysphagia (7%), dehydration (1%), and radiation dermatitis (1%). Despite the small and heterogenous sample, and the varying dosages and modalities administered, reviewers concluded that PBT was safe for the population in question, given the low rates of toxicity.

Ladra and Yock (2014) reviewed the existing clinical and dosimetric data regarding PBT for malignant bone and soft tissue sarcomas in children.(25) Reviewers stated that “the physical properties of proton beam radiotherapy provide a distinct advantage over standard photon radiation by eliminating excess dose deposited beyond the target volume, thereby reducing both the dose of radiation delivered to non-target structures as well as the total radiation dose

delivered to a patient. Dosimetric studies comparing proton plans to IMRT and 3D conformal radiation have demonstrated the superiority of protons in numerous pediatric malignancies and data on long-term clinical outcomes and toxicity is emerging.”

Rombi et al (2012) reported the preliminary clinical outcomes, including late effects, on pediatric Ewing's sarcoma patients treated with PBT at the Francis H. Burr Proton Therapy Center at Massachusetts General Hospital.(26) They performed a retrospective review of the medical records of 30 children with Ewing's sarcoma who were treated with PBT between April 2003 and April 2009. A total of 14 male and 16 female patients with tumors in several anatomic sites were treated with PBT at a median age of 10 years. The median dose was 54 Gy (relative biological effectiveness) with a median follow-up of 38.4 months. The 3-year actuarial rates of event-free survival, local control, and overall survival were 60%, 86%, and 89%, respectively. PBT was acutely well tolerated, with mostly mild-to-moderate skin reactions. At the time of writing, the only serious late effects have been four hematologic malignancies, which are known risks of topoisomerase and anthracycline exposure. The authors concluded that PBT was well tolerated, with few adverse events. Follow-up beyond 3 years will more fully assess tumor control and late effects, but the “preliminary results are encouraging.”

In an article in the 2013 American Society of Clinical Oncology (ASCO) Educational Book, the authors noted that “dosimetric studies of proton radiotherapy compared with best available photon-based treatment show significant dose sparing to developing normal tissues” and “because dose volume parameters are expected to correlate with acute and late toxicity, proton therapy should receive serious consideration as the preferred technique for the treatment of pediatric tumors.”

In a study by Lee et al (2005), treatment plans were evaluated to compare dose distributions and dose-volume histograms for IMRT and PBT in 8 pediatric patients: 3 retinoblastomas, 2 medulloblastomas, and 3 pelvic sarcomas.(27) For each cancer type, protons provided superior target-dose coverage and less radiation to healthy organs at risk. For example, in the patients with pelvic sarcoma, the percent of mean non-target tissue irradiated with protons versus IMRT was 0% compared to 100% for the ovaries, 5% compared to 12% for the bowel, and 9% compared to 29% for the vertebrae. The authors concluded "Protons delivered superior target dose coverage and sparing of normal structures. As dose–volume parameters are expected to correlate with acute and late toxicity, proton therapy should receive serious consideration as the preferred technique for the treatment of pediatric tumors.”

Miralbell et al (2002) assessed the potential influence of improved dose distribution with proton beams compared to conventional or intensity-modulated (IM) X-ray beams on the incidence of treatment-induced secondary cancers in pediatric oncology.(28) Two children, one with a parameningeal rhabdomyosarcoma (RMS) and a second with a medulloblastoma, were used as models for this study. After defining the target and critical structures, treatment plans were calculated and optimized, four for the RMS case (conventional X-ray, IM X-rays, protons, and IM protons) and three for the irradiation of the spinal axis in medulloblastoma (conventional X-ray, IM X-rays, protons). Secondary cancer incidence was estimated using a model based on Publication No. 60 of the International Commission on Radiologic Protection. This model allowed estimation of absolute risks of secondary cancer for each treatment plan based on dose-volume distributions for the nontarget organs. Proton beams reduced the expected incidence of radiation-induced secondary cancers for the RMS patient by a factor of ≥ 2 and for

the medulloblastoma case by a factor of 8 to 15 when compared with either IM or conventional X-ray plans. The authors concluded that “the potential for a significant reduction in secondary cancers with pediatric cancers after using proton beams in the treatment of RMS and MBD in children and adolescents represents an additional argument supporting the development of proton therapy for most radiotherapy indications in pediatric oncology.”

Section Summary: Pediatric Non-Central Nervous System Tumors

Managing pediatric tumors can present unique challenges for many reasons. Although the number of children treated with PBT is relatively small and outcome data are clearly lacking, careful consideration must be given to this vulnerable patient population with regard to initiating the least injurious radiologic treatment approach.

In summary, the benefits of PBT to treat pediatric tumors have been strongly emphasized in the clinical literature. PBT is generally preferred for treating solid tumors in children because PBT delivers targeted doses to tumor tissue with less radiation to the healthy surrounding tissue, sparing critical structures and preventing short- and long-term side effects.

PBT has been shown to have an advantage over conventional photon therapy because of its ability to confine the high-dose treatment area to the tumor volume, thereby minimizing radiation exposure to the surrounding tissues. In children, this is of great significance, as children’s small bodies are more susceptible to radiation-induced malignancies. Additionally, depending on the sites of irradiation, long-term deleterious effects in children can include delays in growth and cognitive development, infertility, neurologic complications, cardiopulmonary compromise, and organ system dysfunction.

CHARGED-PARTICLE (PROTON OR HELIUM ION) RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER

Clinical Context and Test Purpose

The purpose of charged-particle (proton or helium ion) RT in patients who have locally advanced prostate cancer is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this review.

Populations

The relevant population of interest is individuals who have locally advanced prostate cancer (ie, stages T3 or T4). These tumors may be associated with a high rate of local recurrence despite maximal doses of conventional RT.

Interventions

The test being considered is charged-particle RT. Charged-particle therapy is administered in specially equipped treatment centers. PBT can be administered with or without stereotactic techniques

Comparators

The following practices are currently being used to make decisions about localized prostate cancer: other types of radiotherapy, surgical resection, and other types of therapy for localized tumor control.

Outcomes

The general outcomes of interest are OS, disease-free survival, change in disease status (local recurrence), and treatment-related morbidity. Local control and OS would be assessed at 1 and 5 years.

Systematic Reviews

A TEC Assessment (2010) addressed the use of PBT for prostate cancer and concluded that it has not been established whether PBT improves outcomes in any setting for clinically localized prostate cancer.(29) Nine studies were included in the review; 4 were comparative and 5 were noncomparative. There were 2 RCTs, and only one included a comparison group that did not receive PBT. This trial, by Shipley et al (1995), compared treatment with external-beam radiotherapy (EBRT) using photons and either a photon or proton beam boost.(30) After a median follow-up of 61 months, the investigators found no statistically significant differences in OS, disease-specific survival, or recurrence-free survival. In a subgroup of patients with poorly differentiated tumors, there was superior local control with PBT vs photon boost, but survival outcomes did not differ. Actuarial incidence of urethral stricture and freedom from rectal bleeding were significantly better in the photon boost group. The TEC Assessment noted that higher doses were delivered to the proton beam boost group and, thus, better results on survival and tumor control outcomes would be expected. Moreover, the trial was published in the mid-1990s and used 2-dimensional methods of RT, which are now outmoded. The other RCT, known as Proton Radiation Oncology Group, was reported by Zietman et al (2005).(31) They compared conventional- and high-dose conformal therapy using both conformal proton beams, proton boost, and EBRT. After a median follow-up of 8.9 years, there was no statistically significant difference between groups in survival. Biochemical failure (an intermediate outcome) was significantly lower in the high-dose proton beam group than in the conventional-dose proton beam group. The TEC Assessment noted that the outcome (biochemical failure) has an unclear relation to the more clinically important outcome, survival. The rate of acute gastrointestinal tract toxicity was worse with the high-dose proton beam boost.

Kim et al (2013), reported on an RCT of men with androgen-deprivation therapy-naive stage T1, T2, and T3 prostate cancer that compared different protocols for administering hypofractionated PBT.(32) However, without an alternative intervention, conclusions cannot be drawn about the efficacy and safety of PBT. The 5 proton beam protocols used were as follows: arm 1, 60 CGE in 20 fractions for 5 weeks; arm 2, 54 CGE in 15 fractions for 5 weeks; arm 3, 47 CGE in 10 fractions for 5 weeks; arm 4, 35 CGE in 5 fractions for 2.5 weeks; or arm 5, 35 CGE in 5 fractions for 5 weeks. Eighty-two patients were randomized, with a median follow-up of 42 months. Patients assigned to arm 3 had the lowest rate of acute genitourinary toxicity, and those assigned to arm 2 had the lowest rate of late GI toxicity. However, without an alternative intervention, conclusions cannot be drawn about the efficacy and safety of PBT.

Sun et al (2014) assessed therapies for localized prostate cancer, for the Agency for Healthcare Research and Quality.(33) Reviewers compared the risk and benefits of a number of treatments, including: radical prostatectomy, EBRT (standard therapy as well as PBT, 3-dimensional conformal radiotherapy, IMRT, stereotactic body radiotherapy [SBRT]), interstitial

brachytherapy, cryotherapy, watchful waiting, active surveillance, hormonal therapy, and high-intensity focused ultrasound. They concluded that the evidence for most treatment comparisons was inadequate to draw conclusions about comparative risks and benefits. Limited evidence appeared to favor surgery over surveillance or EBRT, and RT plus hormonal therapy over RT alone. Reviewers noted that advances in technologies for many of the treatment options for clinically localized prostate cancer (eg, current RT protocols permit higher doses than those administered in many of the trials included in the report). Moreover, the patient population had changed since most of the studies were conducted. More recently, most patients with localized prostate cancer have been identified using prostate-specific antigen testing and may be younger and healthier than prostate cancer patients identified before such testing existed. Thus, reviewers recommended additional studies to validate the comparative effectiveness of emerging therapies such as PBT, robotic-assisted surgery, and SBRT.

From the published literature, it appears that dose escalation is an accepted concept in treating organ-confined prostate cancer.(34) PBT, using CRT planning or IMRT, is used to provide dose escalation to a more well-defined target volume. However, dose escalation is more commonly offered with conventional EBRT using 3-dimensional conformal radiotherapy or IMRT. Morbidity related to RT of the prostate is focused on the adjacent bladder and rectal tissues; therefore, dose escalation is only possible if these tissues are spared. Even if IMRT or 3-dimensional conformal radiotherapy permits improved delineation of the target volume, if the dose is not accurately delivered, perhaps due to movement artifact, the complications of dose escalation can be serious, because the bladder and rectal tissues are exposed to even higher doses. The accuracy of dose delivery applies to both conventional and PBT.(26)

Liu et al (2021) conducted an analysis of the National Cancer Database (NCDB) for cases of localized prostate cancer treated with definitive radiotherapy between 2004 and 2015.(36) Patients with T1-T3, N0, M0 disease who received first-line treatment to the prostate and/or pelvis were included for analysis. Inclusion of individuals treated with EBRT or PBT was restricted to doses ≥ 60 Gy. The EBRT treatment cohort included individuals receiving 3D-CRT or IMRT and the brachytherapy (BT) treatment cohort allowed for monotherapy or a boost with EBRT. A total of 276,880 patients were identified with median age 68 years and median follow-up of 80.9 months. Patients treated with PBT generally had more favorable prognostic characteristics, including age, comorbidity score, tumor grade, risk group. Ten-year survival rates were 85.6%, 60.1%, and 74% for PBT, EBRT, and BT groups, respectively. In the multivariable analysis, the HR for death was 1.72 (95% CI, 1.51 to 1.96) for EBRT and 1.38 (95% CI, 1.21 to 1.58) for BT compared to PBT ($p < .001$ for all). Generalized propensity score matching of 1860 matched cases from each treatment cohort identified no statistically significant difference in OS between PBT and BT (HR, 1.18; 95% CI, 0.93 to 1.48; $p = .168$). However, EBRT continued to be associated with inferior OS (HR, 1.65; 95% CI, 1.32 to 2.04; $p < .001$) compared to PBT with propensity score matching. Ten-year survival rates in the matched samples were 80.2%, 71.3%, and 78.3% for PBT, EBRT, and BT groups, respectively. EBRT was also associated with inferior OS compared to BT. Older and higher-risk patients were associated with a decreased magnitude of improvement in OS with PBT. A sensitivity analysis determined that the observed difference in OS between PBT and EBRT cohorts was robust to an unmeasured confounder, with a $>400\%$ effect size needed to drive the estimate to nonsignificance. However, the authors note that unmeasured socioeconomic differences and other factors impacting access to proton centers are expected to underpin considerable selection biases. Additionally, the authors conclude that these findings support

the rationale for ongoing studies comparing PBT to IMRT such as the PARTIQoL RCT and the COMPPARE prospective study.

Single-Arm Studies

In 2019, Grewal et al published 4-year outcomes from a prospective phase 2 trial of moderately hypofractionated proton therapy (70 Gy in 28 fractions) for localized prostate cancer.(37) A total of 184 men were followed for a median of 49.2 months. Four-year rates of biochemical-clinical failure-free survival were 93.5% (95% CI, 88 to 100) overall and 94.4% (95% CI, 89 to 100), 92.5% (95% CI, 86 to 100), and 93.8% (95% CI, 88 to 100) among subjects with low-risk, favorable intermediate-risk, and unfavorable, intermediate-risk, respectively. Overall survival was 95.8% (95% CI, 92 to 100) at 4 years, with no statistically significant differences by risk group (log-rank $p>.7$). Four-year cumulative incidence rates of late grade 2 or higher urologic or gastrointestinal toxicities were 7.6% (95% CI, 4 to 13) and 13.6% (95% CI, 9 to 20), respectively. One late grade 3 toxicity occurred, and all late toxicities were transient. Changes in urinary incontinence, irritation, and bowel function were minimal as reflected by International Prostate Symptom Score survey (IPSS) and Expanded Prostate Cancer Index Composite (EPIC) questionnaire scores. Patients receiving anticoagulation reported worse EPIC bowel scores over time ($p<.01$) and patients receiving androgen deprivation therapy reported worse International Index of Erectile Function (IIEF) ($p<.01$) and EPIC sexual ($p=.01$) and hormonal domain ($p=.05$) scores over time.

Section Summary: Localized Prostate Cancer

The evidence on PBT for treating localized prostate cancer includes 2 RCTs and systematic reviews, a single-arm study, and a comparative effectiveness analysis of the National Cancer Database (NCDB). A 2010 TEC Assessment addressed the use of PBT for prostate cancer and concluded that it had not been established whether PBT improves outcomes in any setting for clinically localized prostate cancer. The TEC Assessment included 2 RCTs, only one of which included a comparison group that did not receive PBT. A 2014 comparative effectiveness review concluded that the evidence on PBT for prostate cancer is insufficient. A 2021 comparative effectiveness analysis of the NCDB reported 10-year survival rates of 85.6%, 60.1%, and 74% for PBT, EBRT, and brachytherapy groups, respectively. With propensity score matching, EBRT was associated with inferior survival compared to PBT, and differences between PBT and brachytherapy were not significantly different. Limitations of the published evidence preclude determining the effects of the technology on net health outcome. Ongoing prospective studies comparing PBT to IMRT may alter the conclusions of the TEC Assessment.

CHARGED-PARTICLE (PROTON OR HELIUM ION) RT FOR NON-SMALL-CELL LUNG CANCER

Clinical Context and Test Purpose

The purpose of charged-particle (proton or helium ion) RT in individuals who have non-small-cell lung cancer (NSCLC) is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this review.

Populations

The relevant population of interest is individuals with NSCLC. NSCLC is the most common form of lung cancer, and RT is an essential component of treatment for many patients. The potential benefit of PBT is to reduce radiation toxicity to normal lung tissue and the heart.

Interventions

The therapy being considered is charged-particle (proton or helium ion) RT. Charged-particle therapy is administered in specially equipped treatment centers. PBT can be administered with or without stereotactic techniques.

Comparators

The following practices are currently being used to make decisions about NSCLCs: other types of radiotherapy, surgical resection, or other types of therapy for localized tumor control.

Outcomes

The general outcomes of interest are OS, disease-free survival, change in disease status (local recurrence), and treatment-related morbidity. Local control and OS would be assessed at 1 and 5 years.

Systematic Reviews

A TEC Assessment (2010) assessed the use of PBT for NSCLC.(38) This Assessment compared health outcomes (OS, disease-specific survival, local control, disease-free survival, adverse events) between PBT and SBRT, which is an accepted approach for using RT to treat NSCLC. Eight PBT case series were identified (N=340 patients). No comparative studies, randomized or nonrandomized, were found. For these studies, stage I comprised 88.5% of all patients, and only 39 patients had other stages or recurrent disease. Among 7 studies reporting 2-year OS rates, probabilities ranged between 39% and 98%. At 5 years, the range across 5 studies was 25% to 78%.

The review concluded that the evidence was insufficient to permit conclusions about PBT outcomes for any stage of NSCLC. All PBT studies were case series; no studies directly compared PBT with SBRT. Among study quality concerns, no study mentioned using an independent assessor of patient-reported adverse events; adverse events were generally poorly reported, and details were lacking on several aspects of PBT regimens. The PBT studies were similar in-patient age, but there was great variability in percentages with stage IA cancer, the sex ratio, and the percentage of medically inoperable tumors. There was a high degree of treatment heterogeneity among the PBT studies, particularly with respect to planning volume, total dose, the number of fractions, and the number of beams. Survival results were highly variable. It is unclear whether the heterogeneity of results could be explained by differences in patient and treatment characteristics. In addition, indirect comparisons between PBT and SBRT (eg, comparing separate sets of single-arm studies on PBT and SBRT) might have been distorted by confounding. Absent RCTs, the comparative effectiveness of PBT and SBRT was found to be uncertain. The Assessment noted that adverse events reported after PBT generally fell into several categories: rib fracture, cardiac, esophageal, pulmonary, skin, and soft tissue. Adverse events data in PBT studies are difficult to interpret due to lack of consistent reporting across studies, lack of detail about observation periods, and lack of information about rating criteria and grades.

An indirect meta-analysis by Grutters et al (2010) reviewed in the TEC Assessment found a nonsignificant difference of 9 percentage points between pooled 2-year OS estimates favoring SBRT over PBT for treatment of NSCLC.(39) The nonsignificant difference of 2.4 percentage

points at 5 years also favored SBRT over PBT. Based on separate groups of single-arm studies on SBRT and PBT, it is unclear if this indirect meta-analysis adequately addressed the possible influence of confounding on the comparison of SBRT and PBT.

Pijls-Johannesma et al (2010) conducted a systematic literature review examining use of particle therapy in lung cancer.(40) Study selection criteria included that the series had at least 20 patients and a follow-up period of ≥ 24 months. Eleven studies, all dealing with NSCLC, were selected, 5 investigating protons (n=214) and 6, C-ions (n=210). The proton studies included one Phase 2 study, 2 prospective studies, and 2 retrospective studies. The C-ion studies were all prospective and conducted at the same institution in Japan. No Phase 3 studies were identified. Most patients had stage 1 disease, but because a wide variety of radiation schedules were used, comparisons of results were difficult, and local control rates were defined differently across studies. For proton therapy, 2-year local control rates were 74% and 85% respectively, in the 2 studies reporting this outcome; 5-year local control rates ranged from 57% to 96% (4 studies). Two-year OS ranged from 31% to 74%, and 5-year OS ranged from 31% to 50% (2- and 5-year OS each reported in 4 studies). These local control and survival rates are equivalent or inferior to those achieved with SBRT. Radiation-induced pneumonitis was observed in about 10% of patients. For C-ion therapy, the overall local tumor control rate was 77%, and it was 95% when using a hypofractionated dosing schedule. The 5-year OS and cause-specific survival rates with C-ion therapy were 42% and 60%, respectively. Slightly better results were reported when using hypofractionation (50% and 76%, respectively). Reviewers concluded that, although the results with protons and heavier charged particles were promising, additional well-designed trials would be needed.

Randomized Controlled Studies

Liao et al (2018) conducted a RCT of PSPT versus IMRT in patients with inoperable NSCLC who were candidates for concurrent chemotherapy.(41) Patients were eligible for randomization only if both treatment plans satisfied prespecified dose-volume constraints for organs at risk at the same tumor dose. The majority of enrolled patients were stage IIIA/B. The primary study endpoint was first occurrence of severe (grade ≥ 3) radiation pneumonitis or local failure. Compared to treatment with IMRT (n=92), patients treated with PSPT (n=57) had less lung tissue exposure to doses of 5-10 Gy(RBE [relative biological effectiveness]), increased lung tissue exposure to doses ≥ 20 Gy(RBE), and less heart tissue exposure at all dose levels between 5-80 Gy(RBE). Six patients in each group developed grade ≥ 3 radiation pneumonitis. At 1 year, rates of radiation pneumonitis were 6.5% and 10.5% in IMRT and PSPT groups, respectively (p=.537). Two patients in the IMRT group experienced grade 5 radiation pneumonitis, and no patients in the PSPT groups experienced grade 4 or 5 radiation pneumonitis. At 1 year, rates of local failure were 10.9% and 10.5% in IMRT and PSPT groups, respectively (p=1.0). Combined rates of radiation pneumonitis and local failure were not significantly different between groups (17.4% vs 21.1% for IMRT and PSPT groups, respectively; p=.175). Median OS was 29.5 months and 26.1 months for patients in IMRT and PSPT groups, respectively (p=.297), which is comparable to historical benchmarks. Considerably fewer events occurred in this trial than the 15% rate for radiation pneumonitis and 25% rate for local failure expected from historical data. In an exploratory analysis, the investigators evaluated whether a possible learning curve in the design or delivery of radiation with IMRT or PSPT over time influenced outcomes. Study participants enrolled before and after the trial midpoint in September 2011 were compared. No differences in clinical characteristics were noted for those treated with IMRT whereas the later PSPT group had a higher rate of adenocarcinoma and smaller gross tumor volumes. Combined rates of radiation pneumonitis and local failure at 12 months significantly differed according to time of enrollment

in both IMRT (21.1% [early] vs 18.2% [late]) and PSPT groups (31.0% [early] vs 13.1% [late]). PSPT group radiation pneumonitis events occurred exclusively in the early cohort, whereas IMRT group radiation pneumonitis events occurred throughout the trial. Authors attributed the clinical effectiveness of IMRT in this trial to the introduction of an automated IMRT optimization system during the first year after trial activation. New treatment plans for the 6 patients who developed radiation pneumonitis in the PSPT group were generated post hoc and demonstrated lower mean lung doses for 3 individuals. The authors note that the importance of heart sparing for OS benefit is being elucidated in the ongoing Radiation Therapy Oncology Group (RTOG) 1308 RCT comparing photon versus proton chemoradiation

Nonrandomized Studies

Chang et al (2017) published final results from an open-label phase 2 study of 64 patients with stage III unresectable NSCLC treated with PBT plus concurrent chemotherapy (carboplatin and paclitaxel).⁽⁴²⁾ Median OS was 26.5 months; at 5 years, the OS rate was 29% (95% CI, 18% to 41%). Median progression-free survival was 12.9 months; the 5-year progression-free survival rate was 22% (95% CI, 12% to 32%). At 5 years, 54% of patients had distant metastasis, 28% had locoregional recurrence, and 64% had a recurrence of any type. No grade 5 adverse events were observed, and grade 3 or 4 adverse events were rare. Poor OS was predicted by Karnofsky Performance Status score of 70 to 80, compared with of 90 to 100 (HR=2.48; 95% CI, 1.33 to 4.65; p=0.004). Other predictors of poor OS were stage III cancer (p=0.03), the presence of a tumor in the left lung or right lower lobe (p=0.04), and a retreatment tumor size greater than 7 cm (p=0.03). The use of non-standardized induction and adjuvant chemotherapy as well as the heterogeneity across study populations limit conclusions about treatment efficacy.

Ono et al (2017) published a retrospective case series of 20 patients with lung cancer treated with PBT at a single center between 2009 and 2015.⁽⁴³⁾ In 14 (70%) patients, tumors were clinically inoperable; overall median tumor diameter was 39.5 mm (range, 24-81 mm). PBT was administered 3.2 Gy per fraction. Median follow-up was 27.5 months (range, 12-72 months), and the 1-year OS rate was 95.0% (95% CI, 87.7% to 100%). At 2 years, the OS rate was 73.8% (95% CI, 53.9% to 93.7%); no statistically significant difference was found between operable (n=6) and inoperable patients (n=14) for 2-year OS (p=0.109), although operable patients had better survival rates. At 2 years, local control rate was 78.5% (95% CI, 59.5% to 97.5%), and there were no reported toxicities of grade 3 or higher. The study was limited by small sample size and retrospective design.

Section Summary: Non-Small-Cell Lung Cancer

A 2010 TEC Assessment, which included 8 case series, concluded that the evidence was insufficient to permit conclusions about PBT for any stage of NSCLC. Another systematic review, also published in 2010, only identified case series. Final results from a 2017 open-label phase 2 study included 5-year survival rates for patients who had PBT with concurrent chemotherapy. A 2018 RCT failed to demonstrate superiority of PSPT to IMRT on the combined primary outcome of grade ≥ 3 radiation pneumonitis or local failure. The ongoing

RTOG 1308 RCT is expected to further elucidate the comparative safety and effectiveness of proton versus photon chemoradiation.

CHARGED-PARTICLE (PROTON OR HELIUM ION) RADIOTHERAPY FOR HEAD AND NECK TUMORS, OTHER THAN SKULL-BASED

Clinical Context and Test Purpose

The purpose of charged-particle (proton or helium ion) RT in individuals who have head and neck tumors, other than skull-based, is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this review.

Populations

The relevant population of interest is individuals who have head and neck malignancies. The histology of the malignancies are predominantly of squamous cell type and may arise from, and involve multiple regions, including the oral cavity, pharynx, larynx, nasal cavity and paranasal sinuses, and the major salivary glands.

Interventions

The therapy being considered is charged-particle (proton or helium ion) RT. Charged-particle therapy is administered in specially equipped treatment centers. PBT can be administered with or without stereotactic techniques.

Comparators

The following practices are currently being used to make decisions about head and neck tumors, other than skull-based: other types of radiotherapy, surgical resection, or other types of therapy for localized tumor control.

Outcomes

The general outcomes of interest are OS, disease-free survival, change in disease status (local recurrence), and treatment-related morbidity. Local control and OS would be assessed at 1 and 5 years.

Systematic Reviews

A systematic review by Patel et al (2014) evaluated the literature comparing charged-particle therapy with PBT in the treatment of paranasal sinus and nasal cavity malignant disease.(44) Reviewers identified 41 observational studies that included 13 cohorts treated with charged-particle therapy (N=286 patients) and 30 cohorts treated with photon beam therapy (total N=1186 patients). There were no head-to-head trials. In a meta-analysis, the pooled OS event rate was significantly higher with charged-particle therapy than with photon therapy at the longest duration of follow-up (risk ratio [RR], 1.27; 95% CI, 1.01 to 1.59). Findings were similar for 5-year survival outcomes (RR=1.51; 95% CI, 1.14 to 1.99). Findings were mixed for the outcomes locoregional control and disease-free survival; photon therapy was significantly better for only 1 of the 2 timeframes (longest follow-up or 5-year follow-up). In terms of adverse effects, there were significantly more neurologic toxic effects with charged-particle therapy than with photon therapy ($p<0.001$) but other toxic adverse event rates (eg, eye, nasal, hematologic) did not differ significantly between groups. Reviewers noted that the charged-

particle studies were heterogeneous (eg, type of charged particles [carbon ion, proton]), and delivery techniques. In addition, comparisons were indirect, and none of the studies selected actually compared the 2 types of treatment in the same patient sample.

Nonrandomized Comparative Studies

Youssef et al (2022) conducted a retrospective cohort study comparing outcomes in 292 patients with newly diagnosed nonmetastatic oropharyngeal carcinoma treated with curative-intent intensity-modulated proton therapy (IMPT; n=58) or IMRT (n=234).⁽⁴⁵⁾ Median follow-up was 26 months and 93% of tumors were HPV-p16-positive. There were no significant differences in 3-year rates of OS (97% IMPT vs 91% IMRT; p=.18), progression-free survival (82% IMPT vs 85% IMRT; p=.62) or locoregional recurrence (5% IMPT vs 4% IMRT; p=.59). Incidence of acute toxicities was significantly higher for IMRT compared with IMPT for grade ≥ 2 oral pain (72% IMPT vs 93% IMRT; p<.001), grade ≥ 2 xerostomia (21% IMPT vs 29% IMRT; p<.001), grade ≥ 2 dysgeusia (28% IMPT vs 57% IMRT; p<.001), grade 3 dysphagia (7% IMPT vs 12% IMRT; p<.001), grade ≥ 3 mucositis (53% IMPT vs 57% IMRT; p<.003), grade ≥ 2 nausea (0% IMPT vs 8% IMRT; p=.04), and grade ≥ 2 weight loss (37% IMPT vs 59% IMRT; p<.001). There were no significant differences in chronic grade ≥ 3 toxic effects. Four patients treated with IMRT required a G-tube for longer than 6 months compared to none treated with IMPT.

Blanchard et al (2016) case-matched 50 patients treated with IMPT with 100 patients treated with IMRT who were receiving treatment for oropharyngeal carcinoma.⁽⁴⁶⁾ Patients were followed-up for a median of 32 months. No statistically significant differences in OS (HR, 0.55; 95% CI 0.12-2.50; p = 0.44) or PFS (HR, 1.02; 95% CI, 0.41-2.54; p=.96) were observed. A pre-planned composite endpoint demonstrated reduced risks of grade 3 weight loss or G-tube presence at 3 months (OR 0.44; 95% CI, 0.19-1.0; p=.05) and 1-year after treatment (OR, 0.23; 95% CI, 0.07-0.73; p=.01).

Adverse Events

Zenda et al (2015) reported on late toxicity in 90 patients after PBT for nasal cavity, paranasal sinuses, or skull base malignancies.⁽⁴⁷⁾ Eighty seven of the 90 patients had paranasal sinus or nasal cavity cancer. The median observation period was 57.5 months. Grade 3 late toxicities occurred in 17 patients (19%) and grade 4 occurred in 6 patients (7%). Five patients developed cataracts, and 5 had optic nerve disorders. Late toxicities (other than cataracts) developed a median of 39.2 months after PBT.

Section Summary: Head and Neck Tumors, Other Than Skull-Based

A 2014 systematic review identified only case series and noted that the studies on charged-particle therapy were heterogeneous in terms of the type of particle and delivery techniques. No studies identified that compared charged-particle therapy with other treatments. A case-matched cohort study compared outcomes for oropharyngeal cancer patients receiving IMPT or IMRT. No statistically significant differences in OS or PFS were observed, however, a lower risk for treatment-related adverse events was noted with IMPT. A 2022 retrospective cohort study reported similar findings in patients with nonmetastatic oropharyngeal cancer treated with curative-intent IMPT versus IMRT. Limitations of the published evidence preclude determining the effects of the technology on net health outcome. Ongoing RCTs comparing IMPT to IMRT may elucidate effects on net health outcome.

Intracranial Arteriovenous Malformation (AVM)

The efficacy of proton beam therapy (PBT) for the treatment of AVMs was evaluated in two case series, two retrospective studies, and one prospective, uncontrolled, single-arm clinical trial (Kjellberg, 1983;[48] Kjellberg, 1986;[49] Mehdorn et al, 1988;[50] Seifert, 1994;[51] Barker, 2003;[52], respectively). In these studies, PBT improved symptoms or arrested disease progression in 71% to 98% of patients. The incidence of hemorrhages decreased significantly after treatment but was lower at 2 or more years of follow-up compared with the incidence during the first 2 years of the observation period (Kjellberg, 1986). Procedure-related complications included neurological sequelae (e.g. hemiparesis, visual field defects, and cognitive dysfunction). The complication rates were correlated with treatment dose, advanced age, and thalamic or brainstem involvement (Barker, 2003).

In a retrospective study by Vernimmen et al (2005), 64 patients with AVM were treated with hypofractionated stereotactic PBT for large intracranial AVMs.(53) The AVMs were grouped by volume: <14 cc (26 patients) and > or =14 cc (38 patients). Treatment was delivered with a fixed horizontal 200 MeV proton beam under stereotactic conditions, using a stereophotogrammetric positioning system. The majority of patients were hypofractionated (2 or 3 fractions), and the proton doses were presented as single-fraction equivalent cobalt Gray equivalent doses (SFECyE). The overall mean minimum target volume dose was 17.37 SFECyE, ranging from 10.38-22.05 SFECyE. Analysis by volume group showed obliteration in 67% for volumes <14 cc and 43% for volumes > or =14 cc. Grade IV acute complications were observed in 3% of patients. Transient delayed effects were seen in 15 patients (23%), becoming permanent in 3 patients. One patient also developed a cyst 8-years after therapy. The researchers concluded that “stereotactic proton beam therapy applied in a hypofractionated schedule allows for the safe treatment of large AVMs, with acceptable results. It is an alternative to other treatment strategies for large AVMs.”

Hepatocellular Cancer

Hepatocellular carcinomas (HCC) are aggressive primary malignancies of the liver. All patients should be evaluated for potentially curative therapies including resection, transplantation and ablative treatment. Ablative therapies include radiofrequency ablation, microwave therapy, and alcohol injection. Radiation therapy is considered for patients who are not candidates for resection. There is growing evidence for the use of stereotactic body radiation therapy (SBRT). Charged particle therapy such as proton therapy has also been used in the treatment of hepatocellular carcinoma.

There are no randomized trials comparing PBT to other forms of external radiation. A systematic review and meta-analysis comparing charged particle therapy to conventional radiation and SBRT has been reported. Overall survival, progression-free survival, and local control were equivalent for particle therapy and SBRT. Both charged particle therapy and SBRT were superior to conventional radiation.

A single institution retrospective study compared ablative photon vs proton therapy in patients with unresectable hepatocellular carcinoma. The majority of the proton beam patients were treated as part of a phase II single arm clinical trial (NCT 00976898). The primary endpoint was overall survival. Proton therapy was associated with an improved overall survival of 31 months vs 14 months with photons. The proton-treated patients had a significantly lower risk of nonclassic radiation induced liver disease (RILD) (OR 0.26, P = .03) and development

of RILD at 3 months was significantly associated with worse overall survival. There was no difference in local failure between the two treatment suggesting that the improved survival is related to the decrease in posttreatment liver decompensation. (54)

Proton therapy has been compared to transarterial chemoembolization (TACE) for HCC in a randomized trial. A total of 69 subjects were reported. The primary endpoint was progression-free survival. There was a trend toward improved progression-free survival (48% vs 31%; $P = .06$) favoring protons but no significant difference in overall survival with a median overall survival of 30 months. Total days of hospitalization within 30 days of treatment was 166 days for the 36 TACE patients and 24 days for the proton patients ($P < .001$). (55)

Proton beam therapy is considered medically necessary for the treatment of unresectable HCC with curative intent when there is no evidence of metastatic disease.

Ongoing and Unpublished Clinical Trials

Some currently unpublished trials that might influence this policy are listed in Table 1.

Table 1. Summary of Key Trials NCT No.	Trial Name	Planned Enrollment	Completion Date
<i>Ongoing</i>			
NCT03164460	Phase II Randomized Trial of Stereotactic Onco-Ablative Reirradiation Versus Conventionally Fractionated Conformal Radiotherapy for Patients With Small Inoperable Head and Neck Tumors (SOAR-HN)	100	May 2023
NCT03217188	A Phase II Study of Proton Re-Irradiation for Recurrent Head and Neck Cancer	87	Jul 2023
NCT01629498	Phase I/II Trial of Image-Guided, Intensity-Modulated Photon (IMRT) or Scanning Beam Proton Therapy (IMPT) Both With Simultaneous Integrated Boost (SIB) Dose Escalation to the Gross Tumor Volume (GTV) With Concurrent Chemotherapy for Stage II/III Non-Small Cell Lung Cancer (NSCLC)	100	Sep 2023
NCT01230866	Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer	150	Dec 2023
NCT02923570	A Phase II Randomized Study of Proton Versus Photon Beam Radiotherapy in the Treatment of Unilateral Head and Neck Cancer	108	Oct 2024
NCT01893307	Phase II/III Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) Versus Intensity-Modulated Photon Therapy (IMRT) for the Treatment of Oropharyngeal Cancer of the Head and Neck	442	Aug 2025
NCT01993810	Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer	330	Oct 2025
NCT03561220	A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer (COMPPARE)	3000	Apr 2026
NCT02838602	Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors (ETOILE)	250	Dec 2026
NCT01617161	Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer (PARTIQoL)	454	Dec 2026
ISRCTN16424014	A Trial of Proton Beam Radiotherapy for Oropharyngeal Cancer (TORPEdO)	183	Sep 2028

NCT: national clinical trial

Summary of Evidence

For individuals who have uveal melanoma(s) who receive charged-particle (proton or helium ion) radiotherapy, the evidence includes RCTs and systematic reviews. Relevant outcomes are overall survival, disease-free survival, change in disease status, and treatment-related morbidity. Systematic reviews, including a 1996 TEC Assessment and a 2013 review of randomized and non-randomized studies, concluded that the technology is at least as effective as alternative therapies for treating uveal melanomas and is better at preserving vision. The evidence is sufficient to determine qualitatively that the technology results in an improvement in the net health outcome.

For individuals who have skull-based tumor(s) (ie cervical chordoma and chondrosarcoma) who receive charged-particle (proton or helium ion) radiotherapy, the evidence includes observational studies and systematic reviews. Relevant outcomes are overall survival, disease-free survival, change in disease status, and treatment-related morbidity. A 2007 systematic review found a 5-year OS rate of 81% with proton beam therapy (PBT) compared with 44% with surgery plus photon therapy. In 2016 systematic review of observational studies found 5-year survival rates after proton beam therapy ranging from 67% to 94%. The evidence is sufficient to determine qualitatively that the technology results in a meaningful improvement in the net health outcome. In 2018, a meta-analysis found 5-year and 10-year overall survival rates for proton beam therapy of 78% and 60% compared with 46% and 21% for conventional radiotherapy. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For pediatric non-CNS tumors, PBT delivers targeted doses to tumor tissue with minimal radiation scatter to the healthy surrounding tissue, sparing critical structures and preventing short- and long-term side effects. Although long term outcome data is limited, PBT has been shown to be effective in treating pediatric tumors while sparing critical healthy tissues. Therefore, PBT may be considered established in the treatment of pediatric non-CNS tumors.

For individuals who have localized prostate cancer who receive charged-particle (proton or helium ion) radiotherapy, the evidence includes two RCTs, systematic reviews, a single-arm study, and a database analysis. Relevant outcomes are overall survival, disease-free survival, change in disease status, and treatment-related morbidity. A 2010 TEC Assessment addressed the use of PBT for prostate cancer and concluded that it had not been established whether PBT improves outcomes in any setting for clinically localized prostate cancer. The TEC Assessment included 2 RCTs, only one of which had a comparison group of patients that did not receive PBT. A 2021 analysis of the National Cancer Database reported inferior survival outcomes with EBRT compared to PBT, but no significant survival difference when compared to brachytherapy. A large, ongoing phase 3 RCT comparing proton therapy to IMRT in prostate cancer may alter the conclusions of the TEC Assessment. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have non-small cell lung cancer who receive charged-particle (proton or helium ion) radiotherapy, the evidence includes one RCT, case series and systematic reviews. Relevant outcomes are overall survival, disease-free survival, change in disease status, and treatment-related morbidity. A 2010 TEC Assessment, which included 8 case series, concluded that the evidence was insufficient to permit conclusions about PBT for any stage of

non-small-cell lung cancer. A 2018 RCT failed to demonstrate superiority of passive scattering proton therapy (PSPT) to IMRT on the combined primary outcome of grade ≥ 3 radiation pneumonitis or local failure. An ongoing RCT comparing proton versus photon chemoradiation may alter the conclusions of the TEC Assessment. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have head and neck tumors other than skull-based who receive charged-particle (proton or helium ion) radiotherapy, the evidence includes case series and a systematic review. Relevant outcomes are overall survival, disease-free survival, change in disease status, and treatment-related morbidity. The systematic review noted that the studies on charged-particle therapy were heterogenous in terms of the types of particles and delivery techniques used; further, there are no head-to-head trials comparing charged-particle therapy with other treatments. Ongoing RCTs comparing intensity-modulated proton therapy (IMPT) to IMRT may elucidate effects on net health outcome. The evidence is insufficient to determine that the technology results in a improvement in the net health outcome.

For individuals who have hepatocellular cancer, a systematic review and meta-analysis comparing charged particle therapy to conventional radiation and SBRT has been reported. Overall survival, progression-free survival, and local control were equivalent for particle therapy and SBRT. Both charged particle therapy and SBRT were superior to conventional radiation. Proton beam therapy is considered medically necessary for the treatment of unresectable HCC with curative intent when there is no evidence of metastatic disease. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Supplemental Information

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

CLINICAL INPUT RECEIVED THROUGH PHYSICIAN SPECIALTY SOCIETY AND ACADEMIC MEDICAL CENTER

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

In response to requests while this policy was under review in 2019, clinical input on use of charged-particle (proton or helium ion) beam therapy for various tumor indications was received from 3 respondents, including 2 specialty society-level responses and 1 physician-level response identified by an academic health system. In addition, the specialty society responses included multiple physicians with academic medical center affiliations.

Clinical input and published guidelines support that the use of charged-particle beam therapy provides a clinically meaningful improvement in net health outcomes and is consistent with generally accepted medical practice in the following clinical scenarios:

- Pediatric central nervous system tumors.

Clinical input and published guidelines support that the use of charged-particle beam therapy provides a clinically meaningful improvement in net health outcomes and is consistent with

generally accepted medical practice in the following clinical scenarios, where treatment planning with conventional or advanced photon-based radiotherapy cannot meet dose-volume constraints for normal tissue radiation tolerance:

- Curative treatment of primary or benign solid pediatric non-central nervous system tumors, including Ewing sarcoma;
- Curative treatment of nonmetastatic primary non-small cell lung cancer;
- Head and neck cancers.

Clinical input suggests a possible role of charged-particle beam therapy for the treatment of localized prostate cancer but broad support for this use is pending until the results of an ongoing RCT comparing proton therapy to intensity-modulated radiotherapy (IMRT) are available.

In response to requests, the Blue Cross Blue Shield Association received input from 2 physician specialty societies (4 responses) and 4 academic medical centers while the policy was under review in 2013. There was uniform support for the use of proton beam therapy in pediatric CNS tumors. Two reviewers expressed support for the use of proton beam therapy in pediatric non-CNS tumors. Input on head and neck tumors (non-skull based) was mixed.

PRACTICE GUIDELINES AND POSITION STATEMENT

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

International Particle Therapy Co-operative Group

A 2016 consensus statement by the International Particle Therapy Co-operative Group (PTCOG) offered the following conclusion about proton therapy for non-small-cell lung cancer (NSCLC): "...Promising preliminary clinical outcomes have been reported for patients with early-stage or locally advanced NSCLC who receive proton therapy. However, the expense and technical challenges of proton therapy demand further technique optimization and more clinical studies...."(56)

In 2021, PTCOG published consensus guidelines on particle therapy for the management of head and neck cancer. (57) The following recommendations were made:

- Nasopharynx: "Consider proton therapy whenever feasible. Most advanced treatment, imaging, and adaptation techniques should be used to minimize risk of neurotoxicity, given anatomic location."
- Reirradiation: "Careful evaluation required for each patient to determine risks/benefits of reirradiation. Enrollment in clinical trial encouraged whenever possible."
- Sinonasal: "Consider proton therapy whenever feasible. Most advanced treatment, imaging, and adaptation techniques should be used to minimize risk of neurotoxicity, given anatomic location."

- Postoperative: "Consider proton therapy whenever feasible. Enrollment in clinical trial encouraged whenever possible."
- Oropharynx: "Consider proton therapy whenever feasible. Enrollment in clinical trial encouraged whenever possible."

American College of Radiology

The 2014 American College of Radiology on external beam irradiation in stage T1 and T2 prostate cancer stated:

- "There are only limited data comparing proton-beam therapy to other methods of irradiation or to radical prostatectomy for treating stage T1 and T2 prostate cancer. Further studies are needed to clearly define its role for such treatment.
- There are growing data to suggest that hypofractionation at dose per fraction <3.0 Gy per fraction is reasonably safe and efficacious, and although the early results from hypofractionation/ SBRT (*stereotactic body radiation therapy*) studies at dose per fraction >4.0 Gy seem promising, these approaches should continue to be used with caution until more mature, ongoing phase II and III randomized controlled studies have been completed."(58)

American Urological Association et al

In 2022, the American Urological Association (AUA) and American Society for Radiation Oncology (ASTRO) published evidence-based guidelines for the management of clinically localized prostate cancer.(59) Part III of the guideline discusses principles of radiation therapy. Regarding the use of proton therapy, the guidelines state the following: "Clinicians may counsel patients with prostate cancer that proton therapy is a treatment option, but it has not been shown to be superior to other radiation modalities in terms of toxicity profile and cancer outcomes. (Conditional Recommendation; Evidence Level: Grade C)" The guidelines additionally note that while dosimetric planning studies have indicated that proton therapy can deliver lower integral and mean doses to normal tissues, it has not been established whether these dosimetric differences translate in fewer side effects or improvements in quality of life.

National Comprehensive Cancer Network

Uveal Melanoma

National Comprehensive Cancer Network (NCCN) guidelines for uveal melanoma (v.1.2023) support the use of particle beam therapy for definitive radiotherapy of the primary tumor and that its use is appropriate as upfront therapy after diagnosis, after margin-positive enucleation, or for intraocular or orbital recurrence.(60)

Treatment recommendations for intraocular tumors include:

- "Using protons, 50-70 cobalt Gray equivalent (CGyE) in 4-5 fractions should be prescribed to encompass the planning target volume surrounding the tumor.
- Using carbon ions, 60-85 CGyE in 5 fractions should be prescribed to encompass the planning target volume surrounding the tumor."

Prostate Cancer

NCCN guidelines for prostate cancer (v4.2023) offer the following conclusion on proton therapy: "The NCCN panel believes no clear evidence supports a benefit or decrement to proton therapy over IMRT [intensity-modulated radiotherapy] for either treatment efficacy or long-term toxicity. Conventionally fractionated prostate proton therapy can be considered a reasonable alternative to x-ray-based regimens at clinics with appropriate technology, physics and clinical expertise."(61) The NCCN adds that a prospective randomized trial comparing prostate PBT with x-ray-based IMRT is ongoing and may help to elucidate outcomes, as the evidence to date has not demonstrated a significant difference in benefit, particularly in regard to short and long-term toxicities. The NCCN acknowledges that PBT may deliver less radiation to surrounding tissues (eg, muscle, bone, vessels, fat), but that these tissues do not routinely contribute to the morbidity of prostate radiation. Of greater clinical relevance, is the volume of rectum and bladder that is exposed to radiation. Higher volume, lower dose exposures may minimize risk of long-term treatment morbidity.

Non-Small Cell Lung Cancer

NCCN guidelines for NSCLC (v4.2023) Radiation therapy] has a potential role in all stages of NSCLC as either definitive or palliative therapy... More advanced techniques are appropriate when needed to deliver curative [radiation therapy] safely. These techniques include (but are not limited to)4D-CT and/or PET/CT stimulation, IMRT/VMAT, [image-guided radiation therapy], motion management, and proton therapy... Image-guided radiation therapy is recommended when using proton with steep dose gradients around the target, when [organs at risk] are in close proximity to high-dose regions, and when using complex motion management techniques. "NCCN recommends that highly conformal radiation therapies such as proton therapy be used in the setting of prior radiation therapy, potentially with hyperfractionation, to reduce risk of toxicity. (62)

Head and Neck Cancer

NCCN guidelines for head and neck cancers (v.1.2024) indicate that that proton therapy may be used per the discretion of the treating physician but is an active area of investigation. Proton therapy may be considered when normal tissue constraints cannot be met by photon-based therapy. Otherwise, IMRT or 3D conformal RT is recommended. The safety and efficacy of PBT when highly conformal dose distributions are important has been established, and is particularly important for patient with primary periorbital tumors, tumors invading the orbit, skull base, cavernous sinus, and for patients with intracranial extension or perineural invasion. These treatment approaches are recommended for those being treated with curative intent and/or those with long life expectancies following treatment. However, NCCN adds that "Without "high-quality prospective comparative data, it is premature to conclude that proton therapy has been established as superior to other established radiation techniques such as IMRT, particularly with regard to tumor control.(63) The guidelines suggest that proton therapy can be considered for cancers of the paranasal sinuses and salivary glands if normal tissue constraints cannot be met by conventional photon radiotherapy.

Pediatric Central Nervous System Cancer

NCCN guidelines for pediatric central nervous system cancers (v.1.2023) indicate that proton therapy offers maximal sparing of normal tissue and may be considered for patients with better prognoses (e.g., *IDH1*-mutated tumors, 1p/19q-codeletions, or younger age) as most data are derived from studies involving pediatric cases of low-grade glioma.(64)

Hepatocellular Cancer (HCC)

NCCN guidelines for HCC (v.2.2023) indicate that proton beam therapy may be appropriate in specific situations for HCC. Hypofractionation with photons or protons is an acceptable option for intrahepatic tumors, though treatment at centers with experience is recommended.(65)

American Society for Radiation Oncology

The American Society for Radiation Oncology (ASTRO) (2023) updated its model policy on the medical necessity requirements for the use of proton therapy.(66) ASTRO deemed the following disease sites those for which the evidence frequently supports the use of proton beam therapy:

GENERAL
Benign or malignant tumors or hematologic malignancies in children aged 21 years and younger treated with curative intent and occasionally palliative intent treatment of childhood tumors when at least one of the three criteria noted above under “indications for coverage” apply
Benign or malignant tumors or hematologic malignancies in the adolescent/young adult (AYA) population aged 22 years to 39 years treated with curative intent when at least one of the three criteria noted above under “indications for coverage” apply
Patients with genetic syndromes making total volume of radiation minimization crucial, such as but not limited to NF-1 patients, deleterious ATM mutations, Li-Fraumeni, retinoblastoma patients, and patients with known or suspected genetic mutations. In addition, patients with other genetic mutations who are at increased risk of developing second cancers at or near the same body location such as but not limited to BRCA 1/2, Lynch syndrome, etc.
Medically inoperable patients with a diagnosis of cancer typically treated with surgery where dose escalation is required due to the inability to receive surgery
Re-irradiation cases (where cumulative critical structure dose would exceed tolerance dose)
Primary malignant or benign bone tumors
CENTRAL NERVOUS SYSTEM
Ocular tumors, including intraocular melanomas
Tumors that approach or are located at the base of skull, including but not limited to: <ul style="list-style-type: none"> • Chordoma • Chondrosarcomas • Other histologies arising in this site
Malignant and benign primary CNS tumors excluding IDH wild-type GBM, that are treated with curative intent and with potential for long term prognosis
Primary spine or spinal cord tumors or metastatic tumors to the spine or spinal cord where organ at risk tolerance may be exceeded with photon treatments
Primary and metastatic tumors requiring craniospinal irradiation
HEAD AND NECK
Cancers of the nasopharynx, nasal cavity, paranasal sinuses and other accessory sinuses
Advanced stage and unresectable head and neck cancers
THORACIC
Primary cancers of the esophagus
Primary tumors of the mediastinum, including thymic tumors, mediastinal tumors, mediastinal lymphomas and thoracic sarcomas
Malignant pleural mesothelioma
ABDOMINAL
Hepatocellular cancer and intra-hepatic biliary cancers
Non-metastatic retroperitoneal sarcomas

PELVIC

Advanced and unresectable pelvic tumors with significant pelvic and/or peri-aortic nodal disease

Patient with a single kidney or transplanted pelvic kidney with treatment of an adjacent target volume and in whom maximal avoidance of the organ is critical

U.S. PREVENTIVE SERVICES TASK FORCE RECOMMENDATIONS

Not applicable.

Government Regulations

National:

There is no National Coverage determination on this topic.

Local:

There is a Local Coverage Determination (L34634), "Proton Beam Therapy" Effective for services performed on or after 10/01/2015; Revised 11/01/2016, **Retired 09/01/2017**

Group 1

PROTON beam therapy will be considered medically reasonable and necessary for the following conditions:

1. Unresectable benign or malignant central nervous system tumors to include but not limited to primary and variant forms of astrocytoma, glioblastoma, medulloblastoma, acoustic neuroma, craniopharyngioma, benign and atypical meningiomas, pineal gland tumors, and arteriovenous malformations.
2. Intraocular melanomas
3. Pituitary neoplasms
4. Chordomas and chondrosarcomas
5. Advanced staged and unresectable malignant lesions of the head and neck.
6. Malignant lesions of the Para nasal sinus, and other accessory sinuses
7. Unresectable retroperitoneal sarcoma
8. Solid tumors in children

Group 2

This section defines conditions that are still under investigation and would be covered when part of a clinical trial, registry or both. (See details in coding section)

1. Unresectable lung cancers and upper abdominal/peri-diaphragmatic cancers
2. Advanced stage, unresectable pelvic tumors including those with peri-aortic nodes or malignant lesions of the cervix
3. Left breast tumors
4. Unresectable pancreatic and adrenal tumors
5. Skin cancer with macroscopic perineural/cranial nerve invasion of skull base
6. Unresectable Malignant lesions of the liver, biliary tract, anal canal and rectum
7. Prostate Cancer, Non-Metastatic.

Additional Medicare Guidelines and pre-requirements available (L34634)

https://localcoverage.cms.gov/mcd_archive/view/lcd.aspx?lcdInfo=34634%3a15

(The above Medicare information is current as of the review date for this policy. However, the coverage issues and policies maintained by the Centers for Medicare & Medicare Services [CMS, formerly HCFA] are updated and/or revised periodically. Therefore, the most current CMS information may not be contained in this document. For the most current information, the reader should contact an official Medicare source.)

Related Policies

- Intensity-Modulated Radiation Therapy (IMRT): Abdomen and Pelvis
 - Intensity Modulated Radiation Therapy (IMRT) of the Breast and Lung
 - Intensity-Modulated Radiation Therapy (IMRT): Cancer of the Head and Neck or Thyroid
 - Intensity Modulated Radiation Therapy (IMRT): Central Nervous System Tumors
 - Intensity-Modulated Radiation Therapy (IMRT) of the Prostate
 - Intraocular Radiation Therapy for Age-Related Macular Degeneration
 - Stereotactic Radiosurgery and Stereotactic Body Radiotherapy
-

References

1. Spagnolo F, Caltabiano G, Queirolo P. Uveal melanoma. *Cancer Treat Rev.* Aug 2012;38(5):549-553. PMID 22270078
2. Hawkins BS. Collaborative ocular melanoma study randomized trial of I-125 brachytherapy. *Clin Trials.* Oct 2011;8(5):661-673. PMID 22013172
3. Pereira PR, Odashiro AN, Lim LA, et al. Current and emerging treatment options for uveal melanoma. *Clin Ophthalmol.* 2013;7:1669-1682. PMID 24003303
4. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Charged particle (proton or helium ion) irradiation for uveal melanoma and for chordoma or chondrosarcoma of the skull base or cervical spine. *TEC Assessments 1996; Volume 11, Tab 1.*
5. Wang Z, Nabhan M, Schild SE, et al. Charged particle radiation therapy for uveal melanoma: a systematic review and meta-analysis. *Int J Radiat Oncol Biol Phys.* May 1 2013;86(1):18-26. PMID 23040219
6. Hoffman KE, Yock TI. Radiation therapy for pediatric central nervous system tumors. *J Child Neurol* 2009; 24(11):1387-96.
7. Mishra KK, Quivey JM, Daftari IK, et al. Long-term Results of the UCSF-LBNL randomized trial: charged particle with helium ion versus iodine-125 plaque therapy for choroidal and ciliary body melanoma. *Int J Radiat Oncol Biol Phys.* Jun 1 2015;92(2):376-383. PMID 25841624
8. Lin AJ, Rao YJ, Acharya S, et al. Patterns of care and outcomes of proton and eye plaque brachytherapy for uveal melanoma: Review of the National Cancer Database. *Brachytherapy.* Nov - Dec 2017;16(6):1225-1231. PMID 28966081
9. Toutée A, Angi M, Dureau S et al. Long-Term Visual Outcomes for Small Uveal Melanoma Staged T1 Treated by Proton Beam Radiotherapy.. *Cancers (Basel),* 2019 Jul 28;11(8). PMID 31344948.
10. Lodge M, Pijls-Johannesma M, Stirk L et al. A systematic literature review of the clinical and cost effectiveness of hadron therapy in cancer. *Radiother Oncol* 2007; 83(2):110-22.
11. Zhou J, Yang B, Wang X et al. Comparison of the Effectiveness of Radiotherapy with Photons and Particles for Chordoma After Surgery: A Meta-Analysis.. *World Neurosurg,* 2018 Jun 8;117:46-53. PMID 29879512.
12. Leroy R, Benahmed N, Hulstaert F, et al. Proton therapy in children: a systematic review of clinical effectiveness in 15 pediatric cancers. *Int J Radiat Oncol Biol Phys.* May 1 2016;95(1):267-278. PMID 27084646

12. Upadhyay R, Yadav D, Venkatesulu BP, et al. Risk of secondary malignant neoplasms in children following proton therapy vs. photon therapy for primary CNS tumors: A systematic review and meta-analysis. *Front Oncol.* 2022; 12: 893855. PMID 36033525
13. Peterson RK, King TZ. A systemic review of pediatric neuropsychological outcomes with proton versus photon radiation therapy: A call for equity in access to treatment. *J Int Neuropsychol Soc.* Nov 03 2022: 1-14. PMID 36323679
14. Baliga S, Gallotto S, Bajaj B, et al. Decade-long disease, secondary malignancy, and brainstem injury outcomes in pediatric and young adult medulloblastoma patients treated with proton radiotherapy. *NeuroOncol.* Jun 01 2022; 24(6): 1010-1019. PMID 34788463
15. Indelicato DJ, Bradley JA, Rotondo RL, et al. Outcomes following proton therapy for pediatric ependymoma. *Acta Oncol.* May 2018; 57(5): 644-648. PMID 29239262
16. Bishop AJ, Greenfield B, Mahajan A, et al. Proton beam therapy versus conformal photon radiation therapy for childhood craniopharyngioma: multi-institutional analysis of outcomes, cyst dynamics, and toxicity. *Int J Radiat Oncol Biol Phys.* Oct 1 2014;90(2):354-361. PMID 25052561
17. MacDonald SM, Safai S, Trofimov A et al. Proton radiotherapy for pediatric central nervous system germ cell tumors: early clinical outcomes. *Int J Radiat Oncol Biol Phys.* Jan 1 2011;79(1):121-129. PMID 20452141
18. Moeller BJ, Chintagumpala M, Philip JJ et al. Low early ototoxicity rates for pediatric medulloblastoma patients treated with proton radiotherapy. *Radiat Oncol* 2011; 6:58.
19. Hug EB, Muentner MW, Archambeau JO, et al. Conformal proton radiation therapy for pediatric low-grade astrocytomas. *Strahlenther Onkol.* Jan 2002;178(1):10-17. PMID 11977386
20. Fuss M, Hug EB, Schaefer RA, et al. Proton radiation therapy (PRT) for pediatric optic pathway gliomas: comparison with 3D planned conventional photons and a standard photon technique. *Int J Radiat Oncol Biol Phys.* Dec 1 1999;45(5):1117-1126. PMID 10613303
21. Kozak KR, Adams J, Krejcarek SJ, et al. A dosimetric comparison of proton and intensity-modulated photon radiotherapy for pediatric parameningeal rhabdomyosarcomas. *Int J Radiat Oncol Biol Phys.* May 1 2009;74(1):179-186. PMID 19019562
22. Merchant TE. Proton beam therapy in pediatric oncology. *Cancer J.* Jul-Aug 2009;15(4):298-305. PMID 19672146
23. Timmermann B. Proton beam therapy for childhood malignancies: status report. *Klin Padiatr.* May 2010;222(3):127-133. PMID 20514614
24. Vogel J, Both S, Kirk M, et al. Proton therapy for pediatric head and neck malignancies. *Pediatr Blood Cancer.* Feb 2018;65(2). PMID 29058370
25. Ladra, M. and T.I. Yock, "Proton Radiotherapy for Pediatric Sarcoma," *Cancers* 2014, 6, 112-127.
26. Rombi, B. et "Proton radiotherapy for pediatric Ewing's sarcoma: initial clinical outcomes," *Int J Radiat Oncol Biol Phys.* 2012 Mar 1;82(3):1142-8.
27. Lee, CT, et al "Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: how do protons compare with other conformal techniques?" *Int J Radiat Oncol Biol Phys.* 2005 Oct 1;63(2):362-72.
28. Miralbell, R. et al "Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors," *Int J Radiat Oncol Biol Phys.* 2002 Nov 1;54(3):824-9.
29. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Proton beam therapy for prostate cancer. *TEC Assessments* 2010; Volume 25, Tab 10.
30. Shipley WU, Verhey LJ, Munzenrider JE. Advanced prostate cancer: the results of a randomized comparative trail of high dose irradiation boosting with conformal photons

- compared with conventional dose irradiation using protons alone. *Int J Radiat Oncol Biol Phys* 1995; 32(1):3-12.
31. Zietman AL, DeSilvio ML, Slater JD et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. *Jama* 2005; 294(10):1233-9.
 32. Kim YJ, Cho KH, Pyo HR, et al. A phase II study of hypofractionated proton therapy for prostate cancer. *Acta Oncol*. Apr 2013;52(3):477-485. PMID 23398594
 33. Sun F, Oyesanmi O, Fontanarosa J, et al. Therapies for Clinically Localized Prostate Cancer: Update of a 2008 Systematic Review (Comparative Effectiveness Review No. 146). Rockville, MD: Agency for Healthcare
 34. Nilsson S, Norlen BJ, Widmark A. A systematic overview of radiation therapy effects in prostate cancer. *Acta Oncologica* 2004; 43(4):316-81.
 35. Kuban D, Pollack A, Huang E et al. Hazards of dose escalation in prostate cancer radiotherapy. *Int J Radiat Oncol Biol Phys* 2003; 57(5):1260-8.
 36. Liu Y, Patel SA, Jani AB, et al. Overall Survival After Treatment of Localized Prostate Cancer With Proton Beam Therapy, External-Beam Photon Therapy, or Brachytherapy. *Clin Genitourin Cancer*. Jun 2021;19(3): 255-266.e7. PMID 32972877
 37. Grewal AS, Schonewolf C, Min EJ, et al. Four-Year Outcomes From a Prospective Phase II Clinical Trial of Moderately Hypofractionated Proton Therapy for Localized Prostate Cancer. *Int J Radiat Oncol Biol Phys*. Nov 15 2019; 105(4): 713-722. PMID 31199994
 38. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Proton beam therapy for non-small-cell lung cancer. *TEC Assessments* 2010; Volume 25, Tab 7.
 39. Grutters JP, Kessels AG, Pijls-Johannesma M et al. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a metaanalysis. *Radiother Oncol* 2010; 95(1):32-40.
 40. Pijls-Johannesma M, Grutters J, Verhaegen F, et al. Do we have enough evidence to implement particle therapy as standard treatment in lung cancer? A systematic literature review. *Oncologist*. 2010;15(1):93-103.
 41. Liao Z, Lee JJ, Komaki R, et al. Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. *J Clin Oncol*. Jun 20 2018; 36(18): 1813-1822. PMID 29293386
 42. Chang JY, Verma V, Li M, et al. Proton beam radiotherapy and concurrent chemotherapy for unresectable stage III non-small cell lung cancer: final results of a phase 2 study. *JAMA Oncol*. Aug 10 2017;3(8):e172032. PMID 28727865
 43. Ono T, Yabuuchi T, Nakamura T, et al. High dose hypofractionated proton beam therapy is a safe and feasible treatment for central lung cancer. *Radiol Oncol*. Sep 2017;51(3):324-330. PMID 28959169
 44. Patel SH, Wang Z, Wong WW, et al. Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis. *Lancet Oncol*. Aug 2014;15(9):1027- 1038. PMID 24980873
 45. Youssef I, Yoon J, Mohamed N, et al. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Oropharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy. *JAMA Netw Open*. Nov 01 2022; 5(11): e2241538. PMID 36367724
 46. Blanchard P, Garden AS, Gunn GB, et al. Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - A case matched analysis. *Radiother Oncol*. Jul 2016; 120(1): 48-55. PMID 27342249

47. Zenda S, Kawashima M, Arahira S, et al. Late toxicity of proton beam therapy for patients with the nasal cavity, para-nasal sinuses, or involving the skull base malignancy: importance of long-term follow-up. *Int J Clin Oncol*. Aug 20 2014. PMID 25135461
48. Kjellberg RN, Hanamura T, Davis KR, et al, "Bragg-peak proton-beam therapy for arteriovenous malformations of the brain," *N Engl J Med*. 1983;309:269-274.
49. Kjellberg RN. "Stereotactic Bragg peak proton beam radiosurgery for cerebral arteriovenous malformations," *Ann Clin Res*. 1986;18:17-19.
50. Mehdorn HM, Grote W. "Non-invasive follow-up of patients with intracranial arteriovenous malformations after proton-beam radiation therapy," *Acta Neurochir*. 1988;42:98-102.
51. Seifert V, Stolke D, Mehdorn HM, et al, "Clinical and radiological evaluation of long-term results of stereotactic proton beam radiosurgery in patients with cerebral arteriovenous malformations," *J Neurosurg*. 1994;81:683-689.
52. Barker FG II, Butler WE, Lyons S, et al. "Dose-volume prediction of radiation-related complications after proton beam radiosurgery for cerebral arteriovenous malformations," *J Neurosurg*. 2003;99(2):254-263.
53. Vernimmen FJ. "Stereotactic proton beam therapy for intracranial arteriovenous malformations," *Int J Radiat Oncol Biol Phys*. May 1, 2005; 62(1): 44-52.
54. Sanford, NN, Pursley, J, Noe, B, et al. Protons versus photons for unresectable hepatocellular carcinoma: liver decompensation and overall survival. *Int J Radiat Oncol Biol Phys*. 2019;105(1):64-72.
55. Bush, DA, Smith, JC, Slater, JD, et al. Randomized clinical trial comparing proton beam radiation therapy with transarterial chemoembolization for hepatocellular carcinoma: results of an interim analysis. *Int J Radiat Oncol Biol Phys*. 2016;95(1):477-82.
56. Chang JY, Jabbour SK, De Ruyscher D, et al. Consensus statement on proton therapy in early-stage and locally advanced non-small cell lung cancer. *Int J Radiat Oncol Biol Phys*. May 1 2016;95(1):505-516. PMID 27084663
57. Lin A, Chang JHC, Grover RS, et al. PTCOG Head and Neck Subcommittee Consensus Guidelines on Particle Therapy for the Management of Head and Neck Tumors. *Int J Part Ther*. 2021; 8(1): 84-94. PMID34285938
58. Nguyen PL, Aizer A, Assimos DG, et al. ACR Appropriateness Criteria(R) Definitive External-Beam Irradiation in stage T1 and T2 prostate cancer. *Am J Clin Oncol*. Jun 2014;37(3):278-288. PMID 25180754
59. Eastham JA, Aufferberg GB, Barocas DA, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. Part III: Principles of Radiation and Future Directions. *J Urol*. Jul 2022; 208(1): 26-33. PMID35536141
60. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Uveal Melanoma. Version 1.2023. retrieved October 25, 2023 from https://www.nccn.org/professionals/physician_gls/pdf/uveal.pdf
61. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Prostate Cancer V4.2023. retrieved October 25, 2023 from: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
62. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. V4.2023. retrieved October 25, 2023 from: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
63. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Head and Neck Cancer. V1.2024. retrieved October 25, 2023 from: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf
64. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Pediatric Central Nervous System Cancers. Version 1.2023. retrieved October 25, 2023 from https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf

65. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Hepatocellular Cancer V2.2023. retrieved October 25, 2023 from:
https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf
66. American Society for Radiation Oncology (ASTRO). ASTRO Model Policies: Proton Beam Therapy (PBT). 2013 May.

The articles reviewed in this research include those obtained in an Internet based literature search for relevant medical references through December 2023, the date the research was completed.

Joint BCBSM/BCN Medical Policy History

Policy Effective Date	BCBSM Signature Date	BCN Signature Date	Comments
5/1/08	3/5/08	5/1/08	Joint policy established
11/1/08	10/3/08	10/3/08	Maintenance with diagnostic changes
5/1/11	2/15/11	3/3/11	Routine review with addition of diagnosis malignant neoplasm of the spinal cord; references updated; added treatment planning codes to policy as codes that may also be reported
12/1/12	9/27/12	9/27/12	Routine maintenance; title changed from "Proton Beam Radiotherapy (Charged Particle)" to "Charged-Particle (Proton or Helium Ion) Radiation Therapy"; for clarity, added to Medical Policy Statement and exclusion criteria "non-small-cell lung cancer (NSCLC) at any stage or for recurrence".
3/1/13	12/11/12	12/31/12	Added new code 32701, effective 1/1/13
7/1/13	4/16/13	4/22/13	Added inclusion of pediatric central nervous system tumors; added exclusions for pediatric non-central nervous system tumors and tumors of the head and neck (other than skull-based chordoma and chondrosarcoma); Medical Policy Statement updated to reflect changes in Inclusions/Exclusions; Description, Rationale, and references updated to reflect BCBSA policy
3/1/14	12/10/13	1/6/14	Medical Policy Statement, Exclusion section, and Rationale section revised to exclude treatment for prostate cancer as "not medically necessary" rather than experimental/investigational.
3/1/16	12/10/15	12/16/15	➤ Diverges from BCBSA policy; Drafted to follow AIM criteria.

			<ul style="list-style-type: none"> ➤ Sentence added after the investigational policy statement for localized prostate cancer indicating no incremental benefit when compared to other comparable services. ➤ Added indications all pediatric tumor types and AVMs; added “sacral/lower spine” to MPS and inclusion statement; added statement: “Particularly when plaque brachytherapy is not a feasible option” to inclusion statement with regard to melanoma of the uveal tract; added statement to MPS and inclusions: “Primary or metastatic central nervous system malignancies, such as gliomas, when adjacent to critical structures such as the optic nerve, brain stem, or spinal cord AND when other standard radiation techniques such as IMRT or standard stereotactic modalities would not reduce the risk of radiation damage to the critical structure”; updated Rationale section to reflect support for new indications. ➤ Added references 44-62. ➤ Clinically localized prostate cancer changed from not medically necessary to experimental/investigational ➤ Statement added to MPS: “The evidence does not support that PBRT provides an incremental benefit in the treatment of localized prostate cancer when compared to low cost alternative procedures”.
3/1/17	12/13/16	12/13/16	➤ Routine maintenance
3/1/18	12/12/17	12/12/17	<ul style="list-style-type: none"> ➤ Routine maintenance ➤ Title changed from: “Charged-Particle (Proton or Helium Ion) Radiation Therapy

			➤ MPS update to match current format
3/1/19	12/11/18		➤ Routine maintenance
3/1/20	12/17/19		<ul style="list-style-type: none"> ➤ Routine maintenance ➤ Added language for dosimetric analysis to MPS ➤ Added AIM bullet regarding repeat irradiated tx fields as Inclusion
3/1/21	12/15/20		<ul style="list-style-type: none"> ➤ Routine maintenance ➤ Added inclusion bullet from AIM – Tumor that involves the base of skull and proton therapy is needed to spare the orbit, optic nerve, optic chiasm, or brainstem (sinonasal cancer).
3/1/22	12/14/21		<ul style="list-style-type: none"> ➤ Routine maintenance ➤ Added inclusion bullet from AIM - Hepatocellular carcinoma and intrahepatic cholangiocarcinoma ➤ Deleted the below statement under Inclusions: Primary therapy for melanoma of the uveal tract (iris, choroid or ciliary body), with no evidence of metastasis or extrascleral extension and with tumors up to 24 mm in largest diameter and 14 mm in height, and particularly when plaque brachytherapy is not a feasible option. ➤ Added the below statement to reflect AIM language: To treat melanoma of the uveal tract (including the iris, choroid, or ciliary body) and no evidence of metastasis or extrascleral extension
3/1/23	12/20/22		➤ Routine maintenance (ky)
3/1/24	1/5/24		<ul style="list-style-type: none"> ➤ Routine maintenance ➤ Vendor: eviCore

			<ul style="list-style-type: none"> ➤ Updated Inclusions/Exclusions and MPS to reflect eviCore and Astro guidelines ➤ Divergence from eviCore: <ul style="list-style-type: none"> ➤ Added coverage for in the curative treatment of nonmetastatic primary non-small cell lung cancer to inclusions from BCBSA April, 2023. ➤ Added back to the Inclusions: In the treatment of intracranial arteriovenous malformation not amenable to surgical excision or other conventional forms of treatment OR adjacent to critical structures such as the optic nerve, brain stem or spinal cord. ➤ Removed statement under Exclusions: Lung cancer, including but not limited to when a photon based plan cannot meet tolerances for organs at risk as our JUMP policy covers - In the curative treatment of nonmetastatic primary non-small cell lung cancer. (ky)
--	--	--	--

Next Review Date:

4th Qtr, 2024

BLUE CARE NETWORK BENEFIT COVERAGE
POLICY: CHARGED-PARTICLE (PROTON OR HELIUM ION) RADIOTHERAPY FOR
NEOPLASTIC CONDITIONS

I. Coverage Determination:

Commercial HMO (includes Self-Funded groups unless otherwise specified)	Covered, policy guidelines apply
BCNA (Medicare Advantage)	Refer to the Medicare information under the Government Regulations section of this policy.
BCN65 (Medicare Complementary)	Coinsurance covered if primary Medicare covers the service.

II. Administrative Guidelines:

- The member's contract must be active at the time the service is rendered.
- Coverage is based on each member's certificate and is not guaranteed. Please consult the individual member's certificate for details. Additional information regarding coverage or benefits may also be obtained through customer or provider inquiry services at BCN.
- The service must be authorized by the member's PCP except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Services must be performed by a BCN-contracted provider, if available, except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Payment is based on BCN payment rules, individual certificate and certificate riders.
- Appropriate copayments will apply. Refer to certificate and applicable riders for detailed information.
- CPT - HCPCS codes are used for descriptive purposes only and are not a guarantee of coverage.